{'52WeekChange': 0.25578916,
 'SandP52WeekChange': 0.0644362,
 'address1': '614 McKinley Place NE',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 270.04,
 'askSize': 800,
 'averageDailyVolume10Day': 144275,
 'averageVolume': 261530,
 'averageVolume10days': 144275,
 'beta': 1.137815,
 'beta3Year': None,
 'bid': 269.46,
 'bidSize': 1200,
 'bookValue': 33.872,
 'category': None,
 'circulatingSupply': None,
 'city': 'Minneapolis',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 271.86,
 'dayLow': 267.57,
 'dividendRate': 1.28,
 'dividendYield': 0.0047,
 'earningsQuarterlyGrowth': -0.184,
 'enterpriseToEbitda': 50.357,
 'enterpriseToRevenue': 14.021,
 'enterpriseValue': 10579407872,
 'exDividendDate': 1588896000,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fax': '612-656-4400',
 'fiftyDayAverage': 263.6203,
 'fiftyTwoWeekHigh': 286.68,
 'fiftyTwoWeekLow': 155.17,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': 0.96,
 'floatShares': 38014311,
 'forwardEps': 5.2,
 'forwardPE': 51.936543,
 'fromCurrency': None,
 'fullTimeEmployees': 2200,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0.00487,
 'heldPercentInstitutions': 0.94319,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1561852800,
 'lastMarket': None,
 'lastSplitDate': 975888000,
 'lastSplitFactor': '2:1',
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/bio-techne.com',
 'longBusinessSummary': 'Bio-Techne Corporation, together with its '
                        'subsidiaries, develops, manufactures, and sells '
                        'biotechnology reagents, instruments and services for '
                        'the research and clinical diagnostic markets '
                        'worldwide. The company operates through two segments, '
                        'Protein Sciences, and Diagnostics and Genomics. The '
                        'Protein Sciences segment offers proteins and reagent '
                        'solutions, including cytokines and growth factors, '
                        'antibodies, immunoassays, biologically active small '
                        'molecule compounds, tissue culture reagents, and '
                        'T-Cell activation technologies. This segment also '
                        'provides manual and automated protein analysis '
                        'instruments and immunoassays for use in quantifying '
                        'proteins in various biological fluids. The '
                        'Diagnostics and Genomics segment develops and '
                        'manufactures diagnostic products, including Food and '
                        'Drug Administration -regulated controls, calibrators, '
                        'blood gas and clinical chemistry controls, and other '
                        'reagents for original equipment manufacturers and '
                        'clinical customers, as well as a portfolio of '
                        'clinical molecular diagnostic oncology assays '
                        'comprising the ExoDx Prostate test for prostate '
                        'cancer diagnosis. This segment also manufactures and '
                        'sells tissue-based in-situ hybridization assays for '
                        'research and clinical use. Bio-Techne Corporation has '
                        'partnership with Kantaro Biosciences to develop and '
                        'scale production of COVID-19 serology test. The '
                        'company was formerly known as Techne Corporation and '
                        'changed its name to Bio-Techne Corporation in '
                        'November 2014. Bio-Techne Corporation was founded in '
                        '1976 and is headquartered in Minneapolis, Minnesota.',
 'longName': 'Bio-Techne Corporation',
 'market': 'us_market',
 'marketCap': 10322885632,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_189488',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': 186746000,
 'nextFiscalYearEnd': 1625011200,
 'open': 271.78,
 'openInterest': None,
 'payoutRatio': 0.26950002,
 'pegRatio': 10.62,
 'phone': '612-379-8854',
 'previousClose': 273.42,
 'priceHint': 2,
 'priceToBook': 7.9732523,
 'priceToSalesTrailing12Months': 13.681358,
 'profitMargins': 0.24771999,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 271.86,
 'regularMarketDayLow': 267.57,
 'regularMarketOpen': 271.78,
 'regularMarketPreviousClose': 273.42,
 'regularMarketPrice': 271.78,
 'regularMarketVolume': 66838,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 38223000,
 'sharesPercentSharesOut': 0.0154,
 'sharesShort': 589993,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 552941,
 'shortName': 'Bio-Techne Corp',
 'shortPercentOfFloat': 0.0174,
 'shortRatio': 2.47,
 'startDate': None,
 'state': 'MN',
 'strikePrice': None,
 'symbol': 'TECH',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': 1.28,
 'trailingAnnualDividendYield': 0.004681442,
 'trailingEps': 4.756,
 'trailingPE': 56.785114,
 'twoHundredDayAverage': 226.43503,
 'volume': 66838,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.bio-techne.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '55413'}